DRKS00025797招募中Unknown
Probiotic effects of Bacillus subtilis DSM21097 supplementation on patients after recurrent Clostridioides difficile infection and healthy adults - PROTECT
niversitätsklinikum Frankfurt0 个研究点目标入组 80 人开始时间: 2023年1月10日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 84 Years（—）
- 性别
- All
入选标准
- •1. Age = 18 years
- •2. Patient has had a first episode of CDI* and at least one recurrence
- •3. Patient is scheduled for or currently taking Fidaxomicin, but treatment will be finished upon study entry
- •4. Written informed consent provided prior to inclusion
- •Healthy subjects:
- •1. Age = 18 years
- •2. Written informed consent provided prior to inclusion
- •3. Healthy participant, as determined by screening assessment and Principal Investigator's judgment
排除标准
- •1. Patient with any social or logistical condition, which in the opinion of the investigator may interfere with the conduct of the study, such as incapacity to well understand, not willing to collaborate, or cannot easily be contacted for follow-up assessments
- •2. Planned fecal microbiota transfer (FMT) at inclusion into the study
- •3. Patient with a high risk for antibiotic treatment at study inclusion (except for Fidaxomicin)
- •4. Severely immunocompromised patients, defined as:
- •a. Current or foreseeable neutropenia within the next 14d, defined as <500 Neutrophils/µl
- •b. Scheduled for allogeneic SCT or having received allogeneic SCT within 100d
- •c. Active Graft versus Host Disease requiring immunosuppressive treatment
- •d. Patients with <200 CD4 T-cells/µl
- •e. Use of corticosteroids at a mean dose of 0.3mg/kg/d of prednisone equivalent for >3 weeks
- •f. Treatment with other recognized T-cell immunosuppressants, such as cyclosporine, TNF-alpha blockers, specific monoclonal antibodies (e.g. alemtuzumab), MTX or nucleoside analogues during the last 90 days
- •g. Inherited severe immunodeficiency (e.g.chronic granuloumatous disease or severe combined immunodeficiency)
- •5. Patient requiring intensive care treatment at inclusion
- •6. Patient has one of the following comorbidities: inflammatory bowel disease (ulcerative colitis or Crohn’s disease), irritable bowel syndrome
- •7. Prolonged Fidaxomicin therapy immediately prior to inclusion (> 28 days)
- •8. Patient is allergic to one of the study treatment components: glycerin, gelatin, sunflower lecithin
- •Healthy subjects:
- •1. Participant has a significant history or manifestation of any metabolic, immunological, neurological, cardiovascular, gastrointestinal or other relevant disorder
- •2. Participant has any kind of chronic disease
- •3. Expected or frequent changes in standard medication (contraceptives, thyroid hormones and similar hormonal substitution is allowed, when verified by the Investigator or designee)
- •4. Participant is allergic to one of the study treatment components: glycerin, gelatin, inulin, sunflower lecithin, citric acid, pyridoxine hydrochloride, orange oil, cyanocobalamin, steviol glycosides
研究者
相似试验
已完成
1 期
B. subtilis probiotic reduce S. aureus colonizatioTCTR20210128003The Thailand Research Fund (TRF)683
已完成
不适用
Effect of Bacillus Subtilis DE111® on Daily Bowel MovementsBowel Movement RegulationOccasional ConstipationOccasional DiarrheaNCT04083521Deerland Enzymes50
已完成
不适用
The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's DiseaseCrohn DiseaseNCT04842149Hvidovre University Hospital33
已完成
不适用
Evaluation of Bacillus Subtilis R0179 in Healthy Young AdultsHealthyNCT01802151University of Florida83
进行中（未招募）
1 期
Effects of the probiotic Saccharomyces boulardii CNCM I-745 and the antibiotic Amoxicillin on the gut microbiota of healthy volunteers An open-label, randomized, parallel groups, monocentric studyEUCTR2016-003654-33-DEBIOCODEX48